mix of cr-57 and cr-4098
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01228383)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lyssavirus rabiesImmunity, passive
Lyssavirus rabies immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109564 ↗
Also known as
- cr-57/cr-4098
- mix of cr-57 and cr-4098
- rabies virus-specific monoclonal antibodies
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01228383 | Phase 2 | Dec 1, 2011 | Crucell, Lotus Labs |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 1 | 1 | 1 | 2011 |
| Lotus Labs | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1